221 related articles for article (PubMed ID: 34844413)
1. Will intestinal flora therapy become a new target in type-2 diabetes mellitus? A review based on 13 clinical trials.
Wang F; Zhao T; Wang W; Dai Q; Ma X
Nutr Hosp; 2022 Mar; 39(2):425-433. PubMed ID: 34844413
[TBL] [Abstract][Full Text] [Related]
2. Research progress in the relationship between type 2 diabetes mellitus and intestinal flora.
Ma Q; Li Y; Li P; Wang M; Wang J; Tang Z; Wang T; Luo L; Wang C; Wang T; Zhao B
Biomed Pharmacother; 2019 Sep; 117():109138. PubMed ID: 31247468
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiota: A new target for T2DM prevention and treatment.
Liu L; Zhang J; Cheng Y; Zhu M; Xiao Z; Ruan G; Wei Y
Front Endocrinol (Lausanne); 2022; 13():958218. PubMed ID: 36034447
[TBL] [Abstract][Full Text] [Related]
4. Effects of probiotics on glycemic control and intestinal dominant flora in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis.
Sun Y; Huang Y; Ye F; Liu W; Jin X; Lin K; Wang J; Gao Y; He L
Medicine (Baltimore); 2020 Nov; 99(46):e23039. PubMed ID: 33181668
[TBL] [Abstract][Full Text] [Related]
5. [Research progress of Eubacterium and its metabolite short-chain fatty acids in regulating type 2 diabetes mellitus].
Li WD; Li LS; Lyu MJ; Hu QY; Xiong DQ
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Jan; 57(1):120-124. PubMed ID: 36655268
[TBL] [Abstract][Full Text] [Related]
6. Regulation of the intestinal flora: A potential mechanism of natural medicines in the treatment of type 2 diabetes mellitus.
He L; Yang FQ; Tang P; Gao TH; Yang CX; Tan L; Yue P; Hua YN; Liu SJ; Guo JL
Biomed Pharmacother; 2022 Jul; 151():113091. PubMed ID: 35576662
[TBL] [Abstract][Full Text] [Related]
7. Methanol extract of
Ye X; Wu K; Xu L; Cen Y; Ni J; Chen J; Zheng W; Liu W
Front Endocrinol (Lausanne); 2022; 13():1103972. PubMed ID: 36686454
[TBL] [Abstract][Full Text] [Related]
8. Cyclocarya paliurus polysaccharides alleviate type 2 diabetic symptoms by modulating gut microbiota and short-chain fatty acids.
Yao Y; Yan L; Chen H; Wu N; Wang W; Wang D
Phytomedicine; 2020 Oct; 77():153268. PubMed ID: 32663709
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Intestinal Short-Chain Fatty Acid Metabolism Profile After Probiotics and GLP-1 Treatment for Type 2 Diabetes Mellitus.
Min Q; Wang Y; Jin T; Zhu L; Wu X; Li Y; Wang Y; Xu N
Front Endocrinol (Lausanne); 2022; 13():892127. PubMed ID: 35846273
[TBL] [Abstract][Full Text] [Related]
10. Composite probiotics alleviate type 2 diabetes by regulating intestinal microbiota and inducing GLP-1 secretion in db/db mice.
Wang Y; Dilidaxi D; Wu Y; Sailike J; Sun X; Nabi XH
Biomed Pharmacother; 2020 May; 125():109914. PubMed ID: 32035395
[TBL] [Abstract][Full Text] [Related]
11. Gut Microbiota and Type 2 Diabetes Mellitus: Association, Mechanism, and Translational Applications.
Zhang L; Chu J; Hao W; Zhang J; Li H; Yang C; Yang J; Chen X; Wang H
Mediators Inflamm; 2021; 2021():5110276. PubMed ID: 34447287
[TBL] [Abstract][Full Text] [Related]
12. Correlation between intestinal flora and GLP-1 receptor agonist dulaglutide in type 2 diabetes mellitus treatment-A preliminary longitudinal study.
Liang L; Su X; Guan Y; Wu B; Zhang X; Nian X
iScience; 2024 May; 27(5):109784. PubMed ID: 38711446
[TBL] [Abstract][Full Text] [Related]
13. Probiotics, prebiotics, synbiotics and insulin sensitivity.
Kim YA; Keogh JB; Clifton PM
Nutr Res Rev; 2018 Jun; 31(1):35-51. PubMed ID: 29037268
[TBL] [Abstract][Full Text] [Related]
14. Intestinal Microbiota in Type 2 Diabetes and Chronic Kidney Disease.
Sabatino A; Regolisti G; Cosola C; Gesualdo L; Fiaccadori E
Curr Diab Rep; 2017 Mar; 17(3):16. PubMed ID: 28271466
[TBL] [Abstract][Full Text] [Related]
15. Reductions in Intestinal Taurine-Conjugated Bile Acids and Short-Chain Fatty Acid-Producing Bacteria Might be Novel Mechanisms of Type 2 Diabetes Mellitus in Otsuka Long-Evans Tokushima Fatty Rats.
Yang X; Jiang W; Cheng J; Hao J; Han F; Zhang Y; Xu J; Shan C; Wang J; Yang Y; Yang J; Chang B
Exp Clin Endocrinol Diabetes; 2022 Apr; 130(4):237-247. PubMed ID: 34929746
[TBL] [Abstract][Full Text] [Related]
16. Exercise for the Diabetic Gut-Potential Health Effects and Underlying Mechanisms.
Valder S; Brinkmann C
Nutrients; 2022 Feb; 14(4):. PubMed ID: 35215463
[TBL] [Abstract][Full Text] [Related]
17. Impacts of Plant-derived Secondary Metabolites for Improving Flora in Type 2 Diabetes.
Li LZ; Yan Y; Song Q; Wang Z; Zhang W; Hou Y; Zhang X
Curr Diabetes Rev; 2023; 19(7):e160123212750. PubMed ID: 36650624
[TBL] [Abstract][Full Text] [Related]
18. Berberine Slows the Progression of Prediabetes to Diabetes in Zucker Diabetic Fatty Rats by Enhancing Intestinal Secretion of Glucagon-Like Peptide-2 and Improving the Gut Microbiota.
Wang Y; Liu H; Zheng M; Yang Y; Ren H; Kong Y; Wang S; Wang J; Jiang Y; Yang J; Shan C
Front Endocrinol (Lausanne); 2021; 12():609134. PubMed ID: 34025574
[TBL] [Abstract][Full Text] [Related]
19. Role of natural products and intestinal flora on type 2 diabetes mellitus treatment.
Aydin OC; Aydın S; Barun S
World J Clin Cases; 2023 Jan; 11(1):65-72. PubMed ID: 36687192
[TBL] [Abstract][Full Text] [Related]
20. Potential roles of Glucagon-like peptide-1 and its analogues in cognitive impairment associated with type 2 diabetes mellitus.
Yu ZW; Liu R; Li X; Wang Y; Fu YH; Li HY; Yuan Y; Gao XY
Mech Ageing Dev; 2020 Sep; 190():111294. PubMed ID: 32585235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
